Inocras Introduces Game-Changing MRDVision
Inocras, a prominent player in the field of whole genome sequencing and bioinformatics, has recently launched an innovative minimal residual disease (MRD) detection solution named MRDVision. This cutting-edge technology boasts an impressive limit of detection as low as one-in-a-million, effectively enhancing cancer monitoring.
The Technology Behind MRDVision
MRDVision amalgamates Inocras’s CancerVision cancer profiling platform with Ultima Genomics’ advanced ppmSeq™ technology, delivering highly accurate detection capabilities for circulating tumor DNA. This new assay not only provides a low limit of detection but also streamlines the workflow while maintaining a quick turnaround time—all at an affordable price.
Revolutionizing MRD Testing
What sets MRDVision apart from traditional methods is its ability to detect circulating tumor DNA in the blood post-treatment. Conventional MRD testing typically relies on panel designs that limit the genomic regions analyzed. In contrast, MRDVision’s whole genome approach allows for comprehensive tracking of genetic markers throughout the entire genome. This innovation significantly simplifies the process, enhances efficiency, and provides profound accuracy, paving the way for more data generation per assay.
Advancements in Detection Technology
Central to MRDVision’s capabilities are two pivotal technologies: CancerVision and Ultima Genomics’ ppmSeq™ technology. CancerVision serves as a comprehensive WGS cancer profiling platform, equipped with proprietary bioinformatics that enable the detection of mutations with greater than 99% sensitivity. Moreover, it excels in identifying copy number variations, structural variations, and mutations in non-coding regions with exceptional precision. On the other hand, Ultima’s ppmSeq™ technology ensures the detection of rare single nucleotide variants across the genome, achieving remarkable sensitivity and minimal background error rates, all while simplifying the workflow typical of WGS-based MRD assays.
Future Developments and Clinical Use
Inocras is enthusiastic about presenting the results from the initial analytical validation of MRDVision at prominent gatherings such as the American Society of Human Genetics annual meeting and the Association for Molecular Pathology annual meeting scheduled for November. The company aims for MRDVision to be clinically viable by the end of 2024, with an anticipated commercial launch early in 2025.
CEO Statements on MRDVision Launch
Jehee Suh, the CEO of Inocras, expressed excitement about MRDVision, remarking, "This is the first WGS-based MRD solution developed on Ultima's ppmSeq technology. It's set to be a transformative force in the industry, providing unparalleled sensitivity and genomic coverage, while also being cost-effective and efficient in terms of turnaround time compared to existing MRD technologies."
Ultima Genomics Contributions
Gilad Almogy, the CEO of Ultima Genomics, emphasized the intention behind their unique sequencing architecture designed for large-scale applications, stating, "Our ppmSeq™ technology allows for extremely low limits of detection at a high throughput and low cost. Its precision in detecting single nucleotide variants presents a significant advancement opportunity in oncology testing, and we are eager to see Inocras employ these vital technology features in their pioneering minimal residual disease testing approach."
About Inocras Inc.
Inocras is an AI-focused organization that offers crucial insights for cancer and rare disease patients through whole genome sequencing and bioinformatics. The company presents extensive whole genome testing products, including CancerVision and RareVision, and provides research services tailored for pharmaceutical and biotechnology firms as well as research organizations through a CAP/CLIA certified lab. Inocras is committed to harnessing whole genome data to foster precision health for all.
About Ultima Genomics
Ultima Genomics aims to harness the potential of genomics on a large scale. The objective is to drive genomic information's scale continuously, contributing to remarkable advances in biology and public health. Positioned at the forefront of a biological revolution, the company focuses on increasing availability and usage of genomic data to confront the complexities of biology and its evolving nature. Their innovative sequencing architecture is designed to be scalable far beyond conventional sequencing technologies while reducing the costs of genomic information significantly.
Frequently Asked Questions
What is MRDVision?
MRDVision is a minimal residual disease detection solution introduced by Inocras that leverages whole genome sequencing technologies for enhanced accuracy and efficiency in monitoring cancer.
What technologies does MRDVision utilize?
It combines Inocras’s CancerVision platform with Ultima Genomics’ ppmSeq™ technology to facilitate high-accuracy detection of circulating tumor DNA.
When will MRDVision be available for clinical use?
MRDVision is expected to be clinically available by the end of 2024, with a commercial launch anticipated in early 2025.
How does MRDVision differ from traditional MRD testing?
Unlike traditional methods that utilize specific gene panels, MRDVision employs a comprehensive whole genome approach, allowing for a broader range of genetic tracking.
What are the main benefits of MRDVision?
Key benefits include its low limit of detection, ease of workflow, rapid turnaround time, and the ability to generate extensive data efficiently, which supports various research and discovery initiatives.
